| content | |||||||||||||||||||||||||||||||||||||||||||
 |
|
|
O-2545
|
|
| Systematic (IUPAC) name | |
| (6aR,10aR)-6a,7,10,10a-Tetrahydro-3-[5-(1H-imidazol-1-y l)-1,1-dimethylpentyl]-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C26H36N2O2 |
| Mol. mass | 408.575 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Schedule I (US) |
| Routes | ? |
O-2545 is a drug which is a cannabinoid derivative. It has analgesic effects and is used in scientific research. Unlike most cannabinoids discovered to date, it is water soluble, which gives it considerable advantages over many related drugs. It has high affinity for both CB1 and CB2 receptors, with Ki values of 1.5nM at CB1 and 0.32nM at CB2.1
Legal Status
O-2545 is a Schedule I drug in the USA.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
References
- ^ Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK. Pharmacological characterization of novel water-soluble cannabinoids. Journal of Pharmacology and Experimental Therapeutics. 2006 Sep;318(3):1230-9. PMID 16757541
